Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Messinger

Pain Medicine Charlottesville, VA Medical Doctor

NPI 1801008891 CMS profile 354348

2050 Abbey Rd, Suite A, Charlottesville, VA 22911

Open in the dashboard

General payments

$3,967

88 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Messinger of Charlottesville, VA is reported in the CMS Open Payments database as having received $3,967 across 88 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $750 16
2024 General $1,889 16
2023 General $290 12
2022 General $245 10
2021 General $279 8
2020 General $219 12
2019 General $294 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Messinger
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Richard Messinger were reported at $750. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Richard Messinger Pain Medicine median Middle half National median
2019 $294 $506 $144–$1,566 $163
2020 $219 $315 $96–$934 $114
2021 $279 $452 $134–$1,237 $132
2022 $245 $475 $124–$1,407 $149
2023 $290 $480 $136–$1,384 $160
2024 $1,889 $521 $164–$1,511 $164
2025 $750 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $2,172 66 payments
  2. SI-BONE, Inc. $1,540 8 payments
  3. Abbott Laboratories $80 1 payment
  4. Pfizer Inc. $77 6 payments
  5. Scilex Pharmaceuticals Inc. $71 5 payments
  6. DePuy Synthes Sales Inc. $15 1 payment
  7. Amgen Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,783 85 payments
  2. Travel and Lodging $1,183 3 payments
Products named General payments · program years 2019–2025
  1. WaveWriter Alpha Prime 16 $1,411 37 payments
  2. IFUSE IMPLANT SYSTEM $1,183 3 payments
  3. GENERAL - PAIN MANAGEMENT Pain Management $421 14 payments
  4. GENERAL PAIN MANAGEMENT $193 7 payments
  5. General - Pain Management General - Pain Management_NMD $108 6 payments
  6. PRODIGY $80 1 payment
  7. ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH $71 5 payments
  8. WAVEWRITER ALPHA $20 1 payment
  9. SPECTRA WAVEWRITER $19 1 payment
  10. PEAK $15 1 payment
  11. Other $36 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

696

Median for Interventional Pain Management: 1,220

Drug cost

$7,343

Median for Interventional Pain Management: $39,344

Branded share of claims

11.5%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 184 $1,759
Duloxetine Hcl Generic 56 $1,160
Celecoxib Generic 52 $1,019
Lidocaine Generic 13 $640
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 56 $627
Methylprednisolone Generic 59 $395
Tizanidine Hcl Generic 56 $393
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 24 $302
Diclofenac Sodium Generic 36 $248
Oxycodone Hcl Generic 38 $212

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$494,640

Of which drugs: $15,132

Medicare patients

655

Average age 76

Services billed

9,091

400 women, 255 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 28%
Depression 25%
Ischemic heart disease 23%
Chronic kidney disease 22%
Osteoporosis 20%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 387 2,717 $14,844
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 235 3,193 $287

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

88 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record